KOSUNI KOREA
Korean News in English
Business

Samsung Bioepis' Keytruda Biosimilar: Efficacy and Safety in Focus

Published October 6, 2026 · 2 views
Samsung Bioepis' Keytruda Biosimilar: Efficacy and Safety in Focus

삼성바이오에피스 키트루다: 바이오시밀러의 효과와 안전성

South Korea’s Samsung Bioepis Submits Biosimilar Application for Keytruda

South Korea's Samsung Bioepis has submitted a domestic product approval application for SB27, a biosimilar of Keytruda (a PD-1 inhibitor), the world's leading anticancer drug. This move is part of a strategic response to the global market expansion following Keytruda’s patent expiration, with an application covering 16 indications currently under review.

삼성바이오에피스 키트루다: 바이오시밀러의 효과와 안전성

3rd-Phase Clinical Results Confirm Equivalence

Samsung Bioepis has demonstrated that SB27 shows equivalent safety and efficacy to Keytruda in a 3rd-phase clinical trial. This serves as a differentiation strategy from competitors like Celltrion, laying the groundwork for global market entry.

Keytruda’s Patent Expiration and Market Outlook

Keytruda’s patent is set to expire by the end of 2026, with its market expected to grow to approximately KRW 43 trillion. Samsung Bioepis is currently in the process of making South Korea's first biosimilar application for Keytruda, signaling an intensifying competitive landscape with Celltrion.

On August 10–11, 2026, Samsung Bioepis officially announced its domestic product approval application for SB27. This strategic move aims to secure a competitive position in the global market ahead of Keytruda’s patent expiration.

The Keytruda market is projected to reach around KRW 43 trillion by 2026, with competition between Samsung Bioepis and Celltrion intensifying. Both companies are expected to play leading roles as the market expands following the drug’s patent expiry.

U.S. Regulatory Relaxation and Global Prospects

The U.S. relaxation of biosimilar regulations is anticipated to significantly benefit Samsung Bioepis and Celltrion in the global market, further expanding the competitive landscape within Keytruda’s KRW 43 trillion market.

Samsung Bioepis is also advancing research into next-generation Nectin-4 ADCs, a positioning that has drawn attention for its potential to drive additional innovation beyond the Keytruda market.

Domestic Market Competition Landscape

As South Korea’s first biosimilar application for Keytruda, Samsung Bioepis is currently in the process of seeking approval for SB27. This has intensified competition with Celltrion, and Samsung Bioepis has submitted a product approval request covering 16 indications.

Several media outlets reported on August 10–11, 2026, that Samsung Bioepis had applied for domestic approval of SB27. This aligns with the anticipated market changes due to Keytruda’s patent expiration.

Samsung Bioepis’ SB27 targets 16 indications, a strategy aimed at enhancing competitiveness in the Keytruda market. The company plans to strengthen its global position through this approach.

Based on 3rd-phase clinical results, Samsung Bioepis has demonstrated equivalent efficacy and safety compared to Keytruda, which is seen as a key factor in boosting its competitive edge in the market.

The SB27 application was officially announced between August 10–11, 2026, reflecting a strategy to secure competitiveness in the global market ahead of Keytruda’s patent expiration.

Keytruda Market Size and Competitive Dynamics

The Keytruda market is valued at approximately KRW 43 trillion, with Samsung Bioepis and Celltrion’s biosimilar competition intensifying. Both companies are expected to take leading roles in the market opportunity arising from Keytruda’s patent expiration.

Samsung Bioepis applied for domestic approval of SB27 between August 10–11, 2026, as part of a strategy to differentiate itself from competitors ahead of Keytruda’s patent expiry and global market expansion.

By targeting 16 indications with SB27, Samsung Bioepis aims to secure its position in the world’s top-selling cancer drug market. This is viewed as a key strategic move for enhancing competitiveness.

Samsung Bioepis has validated equivalence based on 3rd-phase clinical results, which is expected to strengthen its competitive edge in the Keytruda market.

U.S. Regulatory Relaxation and Global Expansion

The U.S. easing of biosimilar regulations is expected to bring maximum benefits for Samsung Bioepis and Celltrion in the global market, further expanding competition within Keytruda’s KRW 43 trillion market.

Samsung Bioepis is also advancing next-generation Nectin-4 ADC research, a positioning that has drawn attention as it could drive additional innovation beyond the Keytruda market.

Differentiation Strategy Against Competitors

Samsung Bioepis aims to differentiate itself from competitors through SB27’s application for approval across 16 indications. This strategy is intended to strengthen its position in the Keytruda market.

Based on 3rd-phase clinical results, Samsung Bioepis has demonstrated equivalence, a key factor that enhances competitiveness in the Keytruda market. The company plans to solidify its global position through this approach.

Samsung Bioepis is expected to play a leading role in the KRW 43 trillion Keytruda market following patent expiration. This reflects the company’s strategy of differentiation from competitors to secure market leadership.

Through SB27, Samsung Bioepis is preparing for global market entry targeting 16 indications, which is expected to play a key role in securing competitiveness in the Keytruda market.

Samsung Bioepis officially announced its domestic product approval application for SB27 between August 10–11, 2026. This strategic move responds to global market changes anticipated due to Keytruda’s patent expiration.

Based on 3rd-phase clinical results, Samsung Bioepis has validated equivalence with Keytruda, a development expected to strengthen its competitive position in the market.

Keytruda Patent Expiration and Market Shifts

With Keytruda’s patent set to expire by end-2026, its market is projected to grow to approximately KRW 43 trillion. Samsung Bioepis is currently in the process of making South Korea's first biosimilar application for Keytruda.

Samsung Bioepis’ SB27 targets 16 indications for product approval, a strategy aimed at enhancing competitiveness in the Keytruda market. The company plans to solidify its global position through this approach.

Samsung Bioepis officially announced the domestic application of SB27 between August 10–11, 2026, as part of a strategy to differentiate itself from competitors ahead of Keytruda’s patent expiration and global market expansion.

Based on 3rd-phase clinical results, Samsung Bioepis has validated equivalence with Keytruda, which is seen as a key factor in boosting competitiveness in the market. The company aims to solidify its position globally through this strategy.

Samsung Bioepis is currently applying for domestic product approval of SB27, a strategic move aimed at differentiating itself from competitors within the KRW 43 trillion Keytruda market.

Through SB27, Samsung Bioepis is preparing for global market entry targeting 16 indications, which is expected to maximize utilization of the market opportunity arising from Keytruda’s patent expiration.

Samsung Bioepis’ SB27 has validated equivalence based on 3rd-phase clinical results, a development expected to strengthen its competitive position in the Keytruda market. The company aims to solidify its global standing through this strategy.

Next-Generation Nectin-4 ADC Research Underway

Samsung Bioepis is also advancing next-generation Nectin-4 ADC research, a positioning that has drawn attention for its potential to drive additional innovation beyond the Keytruda market. This research could enable sustained growth even after Keytruda’s patent expires.

The company is developing new treatment options through Nectin-4 ADC research, which is expected to further strengthen Samsung Bioepis’ competitive position in the Keytruda market.

Source References and Related Coverage

Samsung Bioepis' application for domestic approval of SB27 was reported by multiple media outlets between August 10–11, 2026. This reflects coverage of anticipated global market changes following Keytruda’s patent expiration.

The Keytruda market is valued at around KRW 43 trillion, with competition between Samsung Bioepis and Celltrion intensifying. Both companies are expected to take leading roles as the market expands following the drug’s patent expiry.

Samsung Bioepis has validated equivalence for SB27 based on 3rd-phase clinical results, which is seen as a key factor in enhancing competitiveness in the Keytruda market.

With U.S. biosimilar regulatory relaxation, Samsung Bioepis and Celltrion are expected to benefit significantly from global market expansion, further intensifying competition within the KRW 43 trillion Keytruda market.

Samsung Bioepis is preparing for global market entry targeting 16 indications through SB27’s domestic approval application, a strategy designed to maximize utilization of the market opportunity arising from Keytruda’s patent expiration.

SB27 has validated equivalence based on 3rd-phase clinical results, expected to strengthen Samsung Bioepis’ competitive position in the Keytruda market. The company aims to solidify its global standing through this strategy.

Samsung Bioepis is currently applying for domestic approval of SB27, a strategic move aimed at differentiating itself from competitors within the KRW 43 trillion Keytruda market.

By targeting 16 indications and leveraging 3rd-phase clinical results to prove equivalence, Samsung Bioepis aims to differentiate itself from competitors in the global market expansion expected following Keytruda’s patent expiration.

Samsung Bioepis’ SB27 is anticipated to play a leading role in the KRW 43 trillion Keytruda market. This reflects the company’s strategy of differentiation through targeted indications and clinical validation to secure market leadership.

Samsung Bioepis aims to secure global competitiveness through SB27’s domestic approval application, a strategic move designed to maximize utilization of the market opportunity following Keytruda’s patent expiration.

Frequently Asked Questions

What indications is Samsung Bioepis applying for with SB27?

Samsung Bioepis has applied for domestic product approval for SB27 targeting 16 indications. This strategy aims to enhance competitiveness in the Keytruda market.

What is the projected market size following Keytruda’s patent expiration?

The Keytruda market is expected to grow to approximately KRW 43 trillion following its patent expiration. This expansion is driving intensified competition between Samsung Bioepis and Celltrion.

What is the significance of Samsung Bioepis’ next-generation Nectin-4 ADC research?

The next-generation Nectin-4 ADC research is drawing attention as it could drive additional innovation beyond the Keytruda market. This research is part of a strategy to enable sustained growth even after Keytruda’s patent expires.

Read More Related Articles

You can view similar articles on this topic in one place.

View Related Articles

FAQ

What indications is Samsung Bioepis applying for with SB27?

Samsung Bioepis has applied for domestic product approval for SB27 targeting 16 indications. This strategy aims to enhance competitiveness in the Keytruda market.

What is the projected market size following Keytruda’s patent expiration?

The Keytruda market is expected to grow to approximately KRW 43 trillion following its patent expiration. This expansion is driving intensified competition between Samsung Bioepis and Celltrion.

What is the significance of Samsung Bioepis’ next-generation Nectin-4 ADC research?

The next-generation Nectin-4 ADC research is drawing attention as it could drive additional innovation beyond the Keytruda market. This research is part of a strategy to enable sustained growth even after Keytruda’s patent expires.

Korean Source

This article is an English localization of a Korean-language report from BlogScore. Original: 삼성바이오에피스 키트루다: 바이오시밀러의 효과와 안전성